• Home
  • R&D


OliX Pipeline

  • Pipeline
  • OLX101A
  • OLX104C
  • OLX301A
  • OLX301D
  • OLX702A
  • OLX703A


Hypertrophic Scar Treatment

OLX101A is designed to suppress the formation of hypertrophic scars / keloids caused by damage to the dermis and excessive production of collagen fibers. Unlike conventional surgical treatments which are not involved in scar formation mechanisms, OLX101 directly inhibits collagen production by targeting CTGF mRNA.

Target RNA: CTGF

Administration Route: Intradermal Injection

Hypertrophic Scar/Keloids

CTGF is a major factor in fibrotic diseases which promotes the production of extracellular matrix (ECM) proteins, including collagen.
Often, abnormal response (production of extra collagen fibers due to overexpression of CTGF) during the wound healing process leads to the formation of hypertrophic scars/keloids.

Development Status

  • Efficient inhibition of fibrosis identified in animal models
  • Phase 1 clinical trial completed (US, UK)
  • Title Link
    A Randomized, Single Blind, Single Dose, Placebo-controlled, Dose-escalation Phase I Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Intradermal Dosage Form of BMT101 in Healthy Male Volunteers Learn More
    A Phase 1, Single Center, Placebo-controlled, Interventional Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles in Healthy Subjects Compared to Placebo Learn More
  • Phase 2a clinical trial completed (US)
  • Title Link
    Phase 2a Prospective, Randomized, Double-blind, Intra-subject, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy of OLX10010 as an Adjunct Therapy to Reduce the Recurrence of Hypertrophic Scars After Scar Revision Surgery Learn More

Conference Presentation

  • 2016 Journal of Investigative Dermatology
  • Title Download
    Hwang, J., Chang, C., Kim, J. H., Oh, C. T., Lee, H. N., Lee, C., Oh, D., Lee, C., Kim, B., Hong, S. W., & Lee, D. K. (2016). Development of Cell-Penetrating Asymmetric Interfering RNA Targeting Connective Tissue Growth Factor. Journal of Investigative Dermatology, 136(11), 2305-2313. PDF Download
  • 2020 TIDES (20.09)
  • 2021 OTS (Oligonucleotide Therapeutics Society) (21.09)
  • 2023 OPT (Oligonucleotide & Precision Therapeutics) Congress (23.03)